Drug profile · INN
glecaprevir
MAVIRET
glecaprevir (MAVIRET) is a hepatitis c virus serine protease, ns3/ns4a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — glecaprevir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 1
- Programs
- 1
- Data quality
- 0.84
Quick answer
glecaprevir (MAVIRET) is a hepatitis c virus serine protease, ns3/ns4a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Hepatitis C virus serine protease, NS3/NS4A inhibitor
Primary target: Hepatitis C virus serine protease, NS3/NS4A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is glecaprevir?
glecaprevir (MAVIRET) is a hepatitis c virus serine protease, ns3/ns4a inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for glecaprevir?
MAVIRET is a marketed brand name for glecaprevir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of glecaprevir?
glecaprevir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.